Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder

Journal of Medicinal Chemistry

Volumn 57, Issue 4, 2014, Pages 1437-1453

  Moyes, Christopher R ^a   Berger, Richard ^a   Goble, Stephen D ^a   Harper, Bart ^a   Shen, Dong Ming ^a   Wang, Liping ^a   Bansal, Alka ^a,b   Brown, Patricia N ^a   Chen, Airu S ^a   Dingley, Karen H ^a   Di Salvo, Jerry ^a   Fitzmaurice, Aileen ^a   Gichuru, Loise N ^a   Hurley, Amanda L ^a   Jochnowitz, Nina ^a   Miller, Randall R ^a   Mistry, Shruty ^a   Nagabukuro, Hiroshi ^a,d   Salituro, Gino M ^a   Sanfiz, Anthony ^a,c   Stevenson, Andra S ^a   Villa, Katherine ^a,e   Zamlynny, Beata ^a   Struthers, Mary ^a   Weber, Ann E ^a   Edmondson, Scott D ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b SALADAX BIOMEDICAL INC   (United States)

^c PFIZER INC   (United States)

^d TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETANILIDE DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; PYRAZOLE; THIAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONFORMATION; DRUG DESIGN; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; IC 50; IN VITRO STUDY; NONHUMAN; OVERACTIVE BLADDER; PLASMA PROTEIN BINDING; RAT; STRUCTURE ACTIVITY RELATION;

ACETANILIDES; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR CONFORMATION; URINARY BLADDER, OVERACTIVE;

EID: 84896872763     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4017224     Document Type: Article

References (34)

1. Arch, J. R. S.; Ainsworth, A. T.; Cawthorne, M. A.; Piercy, V.; Sennitt, M. V.; Thody, V. E.; Wilson, S. Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs Nature 1984, 309, 163-165
2. Arch, J. R. S.; Ainsworth, A. T. Thermogenic and antiobesity activity of a novel β-adrenoceptor agonist (BRL 26830A) in mice and rats Am. J. Clin. Nutr. 1983, 38, 549-558
3. Sennitt, M. V.; Arch, J. R. S.; Levy, A. L.; Simson, D. L.; Smith, S. A.; Cawthorne, M. A. Anti-hyperglcaemic action of BRL 26830, a novel β-adrenoceptor agonist, in mice and rats Biochem. Pharmacol. 1985, 34, 1279-1285
4. 3-Adrenergic receptor agonists for the treatment of obesity Annu. Rep. Med. Chem. 1998, 33, 193-202
5. Irwin, D. E.; Milsom, I.; Hunskaar, S.; Reilly, K.; Kopp, Z.; Herschorn, S.; Coyne, K.; Kelleher, C.; Hampel, C.; Artibani, W.; Abrams, P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study Eur. Urol. 2006, 50, 1306-1315
6. Abrams, P.; Andersson, K. E. Muscarinic receptor antagonists for overactive bladder BJU Int. 2007, 100, 987-1006
7. Dmochowski, R. Improving the tolerability of anticholinergic agents in the treatment of overactive bladder Drug Safety 2005, 28, 583-600
8. 3-adrenoreceptor in human and rat detrusor muscle J. Urol. 1999, 16, 680-685
9. 3-adrenoreceptor selective agonist, on relaxation of the human detrusor muscle in vitro Neurourol. Urodyn. 2006, 25, 815-819
10. 3-adrenergic receptor agonist CL-316234 on experimental bladder hyperreflexia and detrusor instability in the rat J. Urol. 2001, 166, 1142-1147
11. 3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: Part 5 J. Med. Chem. 2009, 52, 3063-3072
12. 3-adrenergic receptor agonists J. Med. Chem. 2006, 49, 2758-2771
13. 3-adrenergic receptor agonists Bioorg. Med. Chem. Lett. 2007, 17, 6270-6273
14. 3-adrenergic receptor agonists containing substituted 3-indolylalkylamines Bioorg. Med. Chem. Lett. 2003, 13, 1301-1305
15. 3-adrenergic receptor agonists Bioorg. Med. Chem. Lett. 2003, 13, 2191-2194
16. Maruyama, T.; Suzuki, T.; Onda, K.; Hayakawa, M.; Morimoto, H.; Kimizuka, T.; Matsui, T. Preparation of amides as antidiabetics. WO 199920607, 1999.
17. Donaldson, K. H.; Shearer, B. G.; Uehling, D. E. Therapeutic biayrl derivatives useful as beta-3 adrenoreceptor agonists. WO 199965877, 1999.
18. 3 adrenergic receptor agonist, (R)- N -[4-[2-[[2-hydroxy-2-(3- pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl] thiazol-2-yl]benzenesulfonamide J. Med. Chem. 2000, 43, 3832-3836
19. 3-adrenergic receptor, in rats: identification of a novel isethionic acid conjugate Drug Metab. Dispos. 2002, 30, 778-787
20. 3 adrenergic receptor agonists Bioorg. Med. Chem. Lett. 2011, 21, 1865-1870
21. 3- adrenergic receptor agonists with improved rodent pharmacokinetic profiles Bioorg. Med. Chem. Lett. 2010, 20, 1895-1899
22. Svendson, A.; Boll, P. M. Naturally occurring lactones and lactames-V Tetrahedron 1973, 29, 4251-4258
23. Evans, D. A.; Tedrow, J. S.; Shaw, J. T.; Downey, C. W. Diastereoselective magnesium halide-catalyzed anti-aldol reactions of chiral N -acyloxazolidinones J. Am. Chem. Soc. 2002, 124, 392-393
24. Suzuki, M.; Kambe, M.; Tokuyama, H.; Fukuyama, T. Enantioselective total synthesis of FR900482 J. Org. Chem. 2004, 69, 2831-2843
25. 3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore Bioorg. Med. Chem. Lett. 2000, 10, 1971-1973
26. Kalgutkar, A. S.; Driscoll, J.; Zhao, S. X.; Walker, G. S.; Shepard, R. M.; Soglia, J. R.; Atherton, J.; Yu, L.; Mutlib, A. E.; Munchhof, M. J.; Reiter, L. A.; Jones, C. S.; Doty, J. L.; Trevena, K. A.; Shaffer, C. L.; Ripp, S. L. A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif Chem. Res. Toxicol. 2007, 20, 1954-1965
27. Lynch, J. J.; Wallace, A. A.; Stupienski, R. F.; Baskin, E. P.; Beare, C. M.; Appleby, S. D.; Salata, J. J.; Jurkiewicz, N. K.; Sanguinetti, M. C.; Stein, R. B. Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499] J. Pharmacol. Exp. Ther. 1994, 269, 541-554
28. Schoemaker, H.; Hicks, P.; Langer, S. Calcium Channel Receptor Binding Studies for Diltiazem and Its Major Metabolites: Functional Correlation to Inhibition of Portal Vein Myogenic Activity J. Cardiovasc. Pharmacol. 1987, 9, 173-180
29. + Channel Inactivation Gating Circ. Res. 1994, 75, 114-122
30. 3- Adrenoreceptor Agonist: Involvement of Human Efflux and/or Influx Transport Systems Mol. Pharmaceutics 2013, 10, 1783-1794
31. 3-adrenergic receptor agonist and its analogys in rats, dogs and monkeys: improving oral bioavailbility Drug Metab. Dispos. 2002, 30, 771-777
32. Birder, L. A.; de Groat, W. C. Increased c-fos expression in spinal neurons after irritation of the lower urinary tract in the rat J. Neurosci. 1992, 12, 4878-4889
33. Nagabukuro, H.; Degenhardt, A.; Villa, K. L.; Mistry, S. L.; Gichuru, L.; Jochnowitz, N.; Abbadie, C. Auton. Neurosci. 2010, 156, 19-26
34. 3-adrenoreceptor Trends. Pharm. Sci. 1996, 17, 373-381